Evidence map›Paper›PMID 37888903›Full record

ArticleCancer research communications2023

SIX4 Controls Anti-PD-1 Efficacy by Regulating STING Expression.

Beiyuan Liang, Evan H Zhang, Zhen Ye, Hayden Storts, Wei Jin, Xinru Zheng, Hannah Hylton, Olivia Zaleski, Xuanxuan Xing, Wayne Miles and 1 more

Open access · goldAbstract read
In one paragraph

Article in Cancer research communications, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.3field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 1 country.

Beiyuan LiangDepartment of Cancer Biology and Genetics, The Ohio State University, Columbus, Ohio.ORCID 0009-0009-0953-5638
Evan H ZhangDepartment of Cancer Biology and Genetics, The Ohio State University, Columbus, Ohio.ORCID 0009-0001-6591-3973
Zhen YeDepartment of Cancer Biology and Genetics, The Ohio State University, Columbus, Ohio.ORCID 0009-0009-6831-5846
Hayden StortsDepartment of Cancer Biology and Genetics, The Ohio State University, Columbus, Ohio.ORCID 0009-0004-1945-4536
Wei JinDepartment of Cancer Biology and Genetics, The Ohio State University, Columbus, Ohio.ORCID 0009-0004-3803-9725
Xinru ZhengDepartment of Cancer Biology and Genetics, The Ohio State University, Columbus, Ohio.ORCID 0009-0002-7516-8230
Hannah HyltonDepartment of Cancer Biology and Genetics, The Ohio State University, Columbus, Ohio.ORCID 0009-0005-1281-3070
Olivia ZaleskiDepartment of Cancer Biology and Genetics, The Ohio State University, Columbus, Ohio.ORCID 0009-0007-3748-110X
Xuanxuan XingDepartment of Cancer Biology and Genetics, The Ohio State University, Columbus, Ohio.ORCID 0000-0001-7041-0943
Wayne MilesDepartment of Cancer Biology and Genetics, The Ohio State University, Columbus, Ohio.ORCID 0000-0002-2054-5206
Jing J WangDepartment of Cancer Biology and Genetics, The Ohio State University, Columbus, Ohio.ORCID 0009-0005-5145-1156
Cancer Genetics (United States) · USThe Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute · US

Funding

Translational Therapeutics Research Program (TT)P30CA016058 · NCI · OHIO STATE UNIVERSITY · PI Jennifer A. Woyach · 1985 to 2026
$132.3M
The translation regulation of pro-apoptotic genesR01CA251753 · NCI · OHIO STATE UNIVERSITY · PI MILES, WAYNE · 2020 to 2024
$2.0M
The Functional Role of LGR5 in Colon CancerR01CA208063 · NCI · UNIVERSITY OF NEBRASKA MEDICAL CENTER · PI WANG, JING · 2017 to 2022
$1.8M
The Functional Role of GRM3 in Colon CancerR01CA215389 · NCI · UNIVERSITY OF NEBRASKA MEDICAL CENTER · PI WANG, JING · 2017 to 2022
$1.8M
NCI NIH HHS P30 CA016058NCI NIH HHS R01 CA208063NCI NIH HHS R01 CA215389NCI NIH HHS R01 CA251753
6 · The paper itself

Abstract

The cGAS/STING cytosolic DNA-sensing pathway plays a significant role in antitumor immunity. Expression of STING is tightly regulated and commonly reduced or defective in many types of cancer. We have identified SIX4 as a significant regulator of STING expression in colon cancer cells. We showed that knockout of SIX4 decreased STING expression at the mRNA and protein levels while ectopic expression of SIX4 increased STING expression. Depletion of SIX4 led to attenuated STING activation and downstream signaling. Reexpression of SIX4 or ectopic expression of STING in SIX4 knockout cells reversed the effect. Ectopic expression of SIX4 enhanced DMXAA and cGAMP-induced STING activation and downstream signaling. Importantly, decrease of SIX4 expression substantially decreased tumor infiltration of CD8+ T cells and reduced the efficacy of PD-1 antibodies to diminish tumor growth in immune competent mice in vivo. Finally, analysis of The Cancer Genome Atlas colon cancer dataset indicated that tumors with high SIX4 expression were significantly enriched in the Inflammatory Response pathway. SIX4 expression also correlated with expression of multiple IFN-stimulated genes, inflammatory cytokines, and CD8A. Taken together, our results implicate that SIX4 is a principal regulator of STING expression in colon cancer cells, providing an additional mechanism and genetic marker to predict effective immune checkpoint blockade therapy responses. SIGNIFICANCE: Our studies demonstrate that SIX4 is an important regulator of STING expression, providing a genetic marker or a therapeutic target to predict or enhance immune checkpoint blockade therapy responses in colon cancer.

Indexed as

Colonic NeoplasmsImmune Checkpoint InhibitorsAnimalsCytokinesGenetic MarkersMiceSignal TransductionCytokinesGenetic MarkersImmune Checkpoint Inhibitors

Identifiers

PMID37888903
PMCPMC10680432
OpenAlexW4387965761

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.